查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870155

Gabapentin市場依給藥途徑、製劑、劑型、通路、最終用戶和適應症分類－2025-2032年全球預測

Gabapentin Market by Route Of Administration, Formulation, Dosage Form, Distribution Channel, End User, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Gabapentin市場規模將成長至 33 億美元，複合年成長率為 4.50%。

關鍵市場統計數據
基準年 2024 23.2億美元
預計年份：2025年 24.3億美元
預測年份 2032 33億美元
複合年成長率 (%) 4.50%

全面介紹Gabapentin在神經病學和疼痛管理領域不斷發展的臨床應用、商業性趨勢和策略定位

Gabapentin在現代神經病學和疼痛管理中發揮核心作用，可用於治療多種慢性及急性疾病。最初作為抗驚厥藥物引入臨床，如今其治療範圍已擴展至神經病變疼痛綜合症和運動障礙，使其成為全球常用藥物之一。臨床應用模式反映了療效、耐受性和成本等因素的綜合考量，並推動臨床醫師在製劑選擇、劑量策略和給藥途徑等方面不斷改進。

深入分析臨床偏好、製造現代化、監管加強和通路演變如何重塑Gabapentin的競爭格局。

臨床實務、生產技術和監管政策等多種因素的共同作用，正在推動Gabapentin市場格局的變革時期。在臨床上，個人化治療方案的選擇變得日益重要。處方醫師在急性期治療中越來越重視口服和腸外給藥途徑的權衡，而依從性和耐受性則成為長期用藥選擇的重要標準。同時，製劑創新（尤其是緩釋片和新型膠囊基質）正在解決依從性問題，並改善穩態藥物動力學，這些都對處方模式和醫療保險支付方的評估產生了影響。

深入檢驗2025年美國關稅對Gabapentin供應鏈、採購經濟及戰略採購因應措施的累積影響

2025年的政策干預，特別是對醫藥中間體和成品製劑徵收關稅，正累積改變美國Gabapentin的供應鏈經濟格局。對某些活性原料藥（API）和進口商品徵收的關稅措施增加了部分成品和原料的到岸成本，促使企業重新評估採購基礎。為此，生產商和經銷商正在加快多元化步伐，在免稅地區尋找替代供應商，並評估國內API生產，以降低進口關稅和運輸成本波動帶來的風險。

全面的細分分析揭示了給藥途徑、製劑類型、劑型、分銷管道、終端用戶環境和臨床適應症如何影響需求模式。

針對不同細分維度的詳細分析揭示了需求促進因素和商業性影響的差異。根據給藥途徑，口服Gabapentin因其在門診治療中的便利性和良好的依從性，仍然是慢性病管理的主要治療方法；而注射劑型則更適用於急性住院治療以及需要快速調整劑量的情況。口服和注射劑型之間的轉換具有重要的臨床意義，尤其是在醫院環境中，藥物選擇會影響給藥通訊協定和住院時間。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大取得專利的緩釋性Gabapentin製劑在神經病變疼痛管理的應用
  • 非專利藥生產商之間日益激烈的價格競爭正在影響市場利潤率。
  • 新的臨床證據支持Gabapentin用於治療纖維肌痛及仿單標示外疾病。
  • 加強對Gabapentin處方行為的監管，以防止濫用
  • 整合數位化依從性工具以最佳化慢性疼痛患者的Gabapentin治療效果
  • 製藥公司和生技公司進行策略合作，開發Gabapentin聯合治療以提高療效
  • 供應鏈創新縮短了前置作業時間，並確保了非專利處方藥Gabapentin的全球穩定供應。
  • 利用基因譜分析的個人化醫療方法最佳化Gabapentin噴丁給藥方案

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Gabapentin市場依給藥途徑分類

  • 口服
  • 腸外給藥

第9章Gabapentin市場按劑型分類

  • 品牌產品
  • 學名藥

第10章Gabapentin市場按劑型分類

  • 膠囊
    • 硬明膠膠囊
    • 軟膠囊
  • 口服液
  • 藥片
    • 緩釋性
    • 立即發布

第11章Gabapentin市場分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章Gabapentin市場（依最終用戶分類）

  • 診所
  • 居家醫療
  • 醫院

第13章Gabapentin市場依適應症分類

  • 癲癇
  • 神經病變疼痛
    • 糖尿病神經病變
    • 帶狀皰疹後遺症神經痛
  • 不寧腿

第14章Gabapentin市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章Gabapentin市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國Gabapentin丁市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Apotex Inc.
    • Sandoz International GmbH
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Ltd.
    • Zydus Lifesciences Ltd.
    • Torrent Pharmaceuticals Ltd.
    • Alembic Pharmaceuticals Ltd.
    • Lupin Ltd.
Product Code: MRR-3204321AF706

The Gabapentin Market is projected to grow by USD 3.30 billion at a CAGR of 4.50% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.32 billion
Estimated Year [2025] USD 2.43 billion
Forecast Year [2032] USD 3.30 billion
CAGR (%) 4.50%

Comprehensive introduction to gabapentin's evolving clinical applications, commercial dynamics, and strategic positioning across neurology and pain management landscapes

Gabapentin occupies a central role in contemporary neurology and pain management practice, serving multiple indications across chronic and acute care settings. Initially introduced as an anticonvulsant, its therapeutic profile now extends into neuropathic pain syndromes and movement disorders, making it a staple in formularies worldwide. Clinical adoption patterns reflect an intersection of efficacy, tolerability, and cost considerations, driving continuous evolution in how clinicians select formulations, dosing strategies, and routes of administration.

Commercially, gabapentin's trajectory mirrors a broader maturation of the small-molecule analgesic and antiepileptic segments: branded originator products gave way to widespread generic manufacturing, prompting price competition, variations in supply-chain resilience, and a proliferation of dosage forms designed to optimize adherence. At the same time, regulatory scrutiny, patent expirations and reformulation efforts aimed at improving pharmacokinetics have shaped the development pipeline. Taken together, these clinical and commercial forces create a dynamic environment that requires stakeholders to balance therapeutic differentiation against cost-efficiency and regulatory compliance.

This executive synthesis distills the salient drivers of clinical use and commercial performance, highlighting the implications of route-of-administration choices, formulation strategies, dosage form innovations, distribution channel preferences, and indication-specific demand characteristics. It frames the emerging policy and trade developments that are reshaping supply economics, while offering targeted insights for manufacturers, wholesalers, hospital procurement teams, and specialty pharmacies seeking to optimize positioning amid shifting market and regulatory pressures.

Detailed analysis of how clinical preferences, manufacturing modernization, regulatory tightening, and channel evolution are reshaping gabapentin's competitive environment

The gabapentin landscape is undergoing transformative shifts driven by converging forces in clinical practice, manufacturing technology, and regulatory policy. Clinically, there is growing emphasis on individualized therapy selection: prescribers increasingly weigh route-of-administration trade-offs between oral regimens and parenteral approaches for acute interventions, with adherence and tolerability shaping long-term preference. Concurrently, formulation innovation-particularly in extended-release tablets and novel capsule matrices-seeks to address compliance gaps and improve steady-state pharmacokinetics, which in turn affects prescribing patterns and payer evaluations.

Manufacturing and supply-chain modernization have accelerated, with contract manufacturers and large generics players investing in capacity upgrades and quality systems to mitigate shortages and quality-related recalls. This has prompted a reconfiguration of sourcing strategies for active pharmaceutical ingredients and finished dosage forms, increasing collaboration between raw material suppliers, API producers, and finished-dose manufacturers. Regulatory oversight has tightened in parallel, prompting enhanced transparency around manufacturing sites and quality controls; this leads to more rigorous supplier qualification practices and higher upfront compliance costs for new entrants.

Market access and distribution models have also shifted. The rise of online pharmacies as a complementary channel to hospital and retail pharmacies has altered patient acquisition and refill dynamics, necessitating integrated channel strategies that bridge digital engagement with traditional procurement flows. In addition, payer scrutiny and utilization management for neurologic and pain indications are influencing formulary placement and prescribing incentives, encouraging manufacturers to demonstrate value through real-world evidence, patient support programs, and targeted clinical differentiation. These transformative shifts underscore the imperative for all stakeholders to adopt agile operations, invest in quality and differentiation, and align clinical evidence generation with commercial pathways.

In-depth examination of the cumulative effects of 2025 United States tariff measures on gabapentin supply chains, procurement economics, and strategic sourcing responses

Policy interventions in 2025, particularly the introduction of tariffs affecting pharmaceutical intermediates and finished formulations, are cumulatively altering supply-chain economics for gabapentin within the United States. Tariff measures on selected APIs and import categories have raised landed costs for some finished products and raw materials, incentivizing a reassessment of sourcing footprints. In response, manufacturers and distributors have accelerated diversification efforts, seeking alternative suppliers in tariff-exempt jurisdictions and evaluating domestic API production to reduce exposure to import levies and transportation volatility.

These tariff-induced cost pressures have a particularly pronounced effect on lower-margin generic gabapentin products, where distribution and procurement teams must balance price sensitivity with supply continuity. Higher manufacturing overheads and reallocated logistics expenses may prompt tendering cycles to favor suppliers with vertically integrated operations or those holding strategic inventory buffers. At the same time, clinical delivery for indications that require specific dosage forms-such as extended-release tablets or parenteral presentations-may face different levels of impact depending on where the manufacturing steps occur and whether those components fall under tariff schedules.

Regulatory responses and trade policy mitigations are shaping the operational playbook. Firms are engaging more actively with trade advisors to pursue classification reviews, rulings, and temporary exemptions where available, while supply-chain teams are implementing dual-sourcing and nearshoring strategies to reduce tariff exposure. Payers and procurement entities are also responding by re-evaluating contract terms, introducing longer lead-time clauses, and stressing continuity-of-supply clauses to preserve patient care pathways. Taken together, these measures create a more complex procurement environment where cost management must be balanced against clinical risk and regulatory compliance.

Comprehensive segmentation analysis revealing how administration routes, formulation types, dosage forms, distribution channels, end-user settings, and clinical indications sculpt demand patterns

A granular view across segmentation dimensions reveals differentiated demand drivers and commercial implications. Based on route of administration, oral gabapentin remains the dominant modality for chronic management due to outpatient convenience and adherence considerations, while parenteral options are positioned for acute inpatient settings or situations requiring rapid titration. Transition pathways between oral and parenteral forms are clinically meaningful, particularly in hospital settings where formulary choices influence dosing protocols and length of stay.

Based on formulation, branded offerings continue to leverage perception of consistent supply and patient support services, whereas generic formulations drive volume-based procurement through cost advantages. Manufacturers and payers negotiate around the trade-offs between price and perceived product reliability, with branded suppliers often investing in services and patient adherence programs to maintain differentiated value propositions. Based on dosage form, capsules, oral solutions, and tablets each present unique market dynamics: capsules-further segmented into hard gelatin and soft gelatin types-offer formulation flexibility and patient acceptability, oral solutions support pediatric and dysphagia populations, and tablets-divided into extended-release and immediate-release variants-address adherence and pharmacokinetic optimization needs. These dosage-form distinctions inform manufacturing complexity, packaging choices, and channel stocking decisions.

Based on distribution channel, hospital pharmacies prioritize formulary equivalence and supply continuity, online pharmacies emphasize convenience, refill management, and direct-to-patient services, while retail pharmacies balance walk-in demand with prescription volume and local prescriber relationships. Each channel requires tailored logistics, inventory strategies, and patient education approaches. Based on end user, clinics, home care providers, and hospitals display divergent purchasing cycles and clinical protocols; clinics and hospitals often engage in tendered purchasing with volume commitments and payer negotiations, while home care channels prioritize ease of administration and patient support. Finally, based on indication, epilepsy, neuropathic pain, and restless leg syndrome create distinct utilization patterns: neuropathic pain subdivides into diabetic neuropathy and postherpetic neuralgia, each with unique clinical pathways and comorbidity considerations that affect dosing strategies, real-world outcomes measurement, and payer positioning. These segmentation insights collectively inform product development priorities, channel strategies, and clinical engagement plans for manufacturers and distributors alike.

Strategic regional intelligence that contrasts regulatory regimes, procurement models, and distribution realities across the Americas, Europe Middle East & Africa, and Asia-Pacific territories

Regional dynamics shape both clinical practice and commercial strategy for gabapentin, with the Americas, Europe, Middle East & Africa, and Asia-Pacific each presenting distinct regulatory, payer, and manufacturing considerations. In the Americas, strong outpatient care infrastructure and mature retail and online pharmacy channels support high-volume generic distribution, while hospital procurement emphasizes continuity and therapeutic interchange protocols. Pricing pressures coexist with advanced pharmacovigilance systems, prompting manufacturers to align post-marketing surveillance and patient-support initiatives with payer requirements.

In Europe, Middle East & Africa the regulatory landscape varies widely across sub-regions: European markets are characterized by rigorous approval pathways, centralized pharmacovigilance, and differentiated reimbursement mechanisms that favor evidence of therapeutic benefit and cost-effectiveness. The Middle East exhibits demand driven by expanding hospital networks and increasing adoption of standardized neurology protocols, whereas parts of Africa face access constraints and supply reliability challenges that elevate the importance of robust distribution partnerships and quality-assured sourcing. Cross-border regulatory harmonization efforts and regional procurement mechanisms influence how manufacturers design market-entry and supply strategies.

In the Asia-Pacific region, diverse market sophistication levels create both high-growth opportunities and operational complexity. Developed markets within the region show rapid uptake of digital pharmacy models and value-based procurement, while emerging markets balance affordability considerations with expanding clinical capacity. The region is also a key node for global manufacturing and API supply, with implications for tariffs, trade policy, and contingency planning. Collectively, these regional insights underline the need for differentiated market strategies that account for regulatory nuance, procurement models, and local clinical practice patterns.

Insightful evaluation of how manufacturing scale, regulatory compliance, formulation differentiation, and strategic partnerships drive competitive advantage among gabapentin suppliers

Competitive dynamics among companies engaged with gabapentin center on scale economics in manufacturing, portfolio breadth across dosage forms, and the ability to deliver dependable supply under tightening regulatory scrutiny. Originator brands historically established clinical recognition and patient-support frameworks, which many generic manufacturers seek to replicate through service offerings and enhanced packaging. Large generics firms have leveraged manufacturing scale to compete on price while investing selectively in differentiated formulations such as extended-release tablets and specialty capsules to capture niche segments.

Strategic partnerships and contract manufacturing relationships have proliferated as firms optimize capacity utilization and de-risk supply. Companies with integrated API capabilities demonstrate resilience when trade disruptions or tariff pressures emerge, while those reliant on third-party suppliers face higher negotiation complexity and potential exposure. In addition, firms investing in quality management systems and regulatory compliance can convert reliability into commercial advantage, particularly with hospital and institutional buyers where tender outcomes favor proven suppliers.

On the innovation front, companies pursuing formulation improvements, pediatric-friendly presentations, and adherence-enhancing packaging aim to distinguish their offerings in congested generic markets. Corporate strategies also include geographic diversification of manufacturing and sales footprints, mergers and acquisitions to consolidate capabilities, and collaborations with specialty distributors and digital health platforms to expand access and patient engagement. These company-level behaviors collectively define a competitive landscape where operational excellence, regulatory readiness, and selective differentiation determine long-term positioning.

Actionable strategic recommendations for manufacturers, distributors, and payers to enhance supply resilience, clinical differentiation, and channel integration in gabapentin portfolios

Industry leaders should adopt a multi-faceted strategy that balances operational resilience, clinical differentiation, and channel optimization to maintain competitiveness in the gabapentin space. Strengthening supplier qualification programs and diversifying API sourcing will reduce exposure to trade-induced cost shocks and capacity constraints, while investments in domestic or nearshore manufacturing capacity can serve as a hedge against import tariffs and logistical disruptions. Coupled with inventory optimization and demand-forecasting enhancements, these operational moves will protect continuity of patient care and institutional contracts.

On the commercial side, prioritizing dosage-form differentiation-such as extended-release tablets and patient-friendly oral solutions-can create pockets of value that extend beyond price competition. Demonstrating real-world outcomes and adherence benefits through targeted evidence generation will enhance formulary positioning and payer conversations. In parallel, building robust channel strategies that integrate hospital pharmacy relationships, retail pharmacy partnerships, and online pharmacy capabilities will capture diverse patient touchpoints and strengthen refill retention. Digital patient support, adherence tools, and targeted clinician education programs can further unlock value by reducing discontinuation rates and improving long-term use.

Finally, proactive engagement with policymakers and trade advisors to navigate tariff classifications and seek exemptions where appropriate can mitigate near-term cost impacts. Executing strategic collaborations with contract manufacturers and quality-focused partners will accelerate capacity scaling while preserving compliance. By combining operational hedging, evidence-driven differentiation, and integrated channel management, industry leaders can secure sustainable advantage in a market shaped by regulatory change and evolving clinical practice.

Transparent mixed-methods research approach integrating primary expert interviews, regulatory and trade data reviews, and scenario analysis to produce robust strategic insights

The research underpinning this executive synthesis employed a mixed-methods approach designed to triangulate industry intelligence across primary and secondary sources. Primary research included structured interviews with clinical experts, hospital pharmacy directors, supply-chain managers, and distribution executives to capture real-world procurement practices, clinical preferences across indications, and channel-specific operational constraints. These interviews provided qualitative depth on formulary decision drivers, adherence challenges, and the practical implications of sourcing shifts under tariff pressures.

Secondary research encompassed review of regulatory filings, product labeling, and publicly available pharmacovigilance data to verify clinical indications, dosing paradigms, and safety profiles. Trade and customs datasets informed analysis of import/export flows and tariff exposure, while patent and regulatory-action databases were consulted to map intellectual property landscapes and approval histories where relevant. Financial disclosures and investor presentations from publicly listed manufacturers offered context on capacity expansion, capital allocation, and strategic partnerships.

Analytic techniques combined thematic coding of interview transcripts with cross-sectional comparison of regulatory and trade datasets to identify systemic patterns. Scenario analysis explored plausible responses to tariff shocks and supply disruptions, while sensitivity checks ensured robustness of strategic inferences. Throughout, the methodology prioritized transparency and reproducibility by documenting source provenance, interview protocols, and assumptions used in qualitative synthesis. This approach produced a grounded, multi-dimensional view of market dynamics while ensuring that practical recommendations remained closely tied to observable industry behaviors and verified regulatory information.

Concluding synthesis that distills operational imperatives, clinical differentiation levers, and regional nuances essential for sustaining gabapentin access and commercial resilience

In conclusion, gabapentin remains a therapeutically vital and commercially complex product class that sits at the intersection of clinical need, manufacturing realities, and policy developments. The prevailing trends-growing emphasis on adherence-focused formulations, heightened regulatory expectations for manufacturing quality, and trade-policy volatility-collectively require manufacturers and distributors to adopt resilient, evidence-informed strategies. Those able to secure reliable supply chains, demonstrate clinical value beyond price, and execute multi-channel distribution plans will find the preconditions for sustainable advantage.

The interplay between route of administration choices, formulation differentiation, dosage form innovation, and distribution channel selection creates multiple levers for strategic action. Regional differences in regulatory and procurement models further underscore the importance of localized strategies rather than one-size-fits-all approaches. Firms that invest in quality systems, diversify sourcing, and prioritize real-world evidence generation will be best positioned to navigate tariff-related cost pressures and shifting payer expectations.

Ultimately, the next phase of competition in the gabapentin environment will favor entities that combine operational excellence with targeted clinical and commercial differentiation. Proactive planning today-grounded in the segmentation and regional insights outlined here-will be instrumental in protecting patient access and securing long-term commercial resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of patented extended-release gabapentin formulations in neuropathic pain management
  • 5.2. Escalating price competition among generic gabapentin manufacturers affecting market margins
  • 5.3. Emerging clinical evidence supporting gabapentin use in treating fibromyalgia and off-label conditions
  • 5.4. Regulatory agencies intensifying monitoring of gabapentin prescribing practices to curb misuse
  • 5.5. Integration of digital adherence tools to optimize gabapentin therapy outcomes in chronic pain patients
  • 5.6. Strategic partnerships between pharma and biotech firms to develop gabapentin combination therapies with improved efficacy
  • 5.7. Supply chain innovations reducing lead times and ensuring consistent availability of gabapentin generics globally
  • 5.8. Personalized medicine approaches leveraging genetic profiling to tailor gabapentin dosing regimens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gabapentin Market, by Route Of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. Gabapentin Market, by Formulation

  • 9.1. Branded
  • 9.2. Generic

10. Gabapentin Market, by Dosage Form

  • 10.1. Capsules
    • 10.1.1. Hard Gelatin
    • 10.1.2. Soft Gelatin
  • 10.2. Oral Solution
  • 10.3. Tablets
    • 10.3.1. Extended Release
    • 10.3.2. Immediate Release

11. Gabapentin Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gabapentin Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Gabapentin Market, by Indication

  • 13.1. Epilepsy
  • 13.2. Neuropathic Pain
    • 13.2.1. Diabetic Neuropathy
    • 13.2.2. Postherpetic Neuralgia
  • 13.3. Restless Leg Syndrome

14. Gabapentin Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gabapentin Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gabapentin Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Teva Pharmaceutical Industries Ltd.
    • 17.3.2. Viatris Inc.
    • 17.3.3. Apotex Inc.
    • 17.3.4. Sandoz International GmbH
    • 17.3.5. Sun Pharmaceutical Industries Ltd.
    • 17.3.6. Cipla Ltd.
    • 17.3.7. Zydus Lifesciences Ltd.
    • 17.3.8. Torrent Pharmaceuticals Ltd.
    • 17.3.9. Alembic Pharmaceuticals Ltd.
    • 17.3.10. Lupin Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GABAPENTIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS GABAPENTIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS GABAPENTIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS GABAPENTIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 331. ASEAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. ASEAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. ASEAN GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. ASEAN GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. ASEAN GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 336. ASEAN GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 339. GCC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 340. GCC GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 341. GCC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. GCC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. GCC GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 344. GCC GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 345. GCC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 346. GCC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 347. GCC GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 348. GCC GABAPENTIN MARKET SIZE, BY CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 349. GCC GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 350. GCC GABAPENTIN MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 351. GCC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. GCC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. GCC GABAPENTIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 354. GCC GABAPENTIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 355. GCC GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 356. GCC GABAPENTIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 357. GCC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 358. GCC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 359. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 360. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 361. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 362. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 363. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 364. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 365. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 366. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 367. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 368. EUROPEA